PROBLEM TO BE SOLVED: To provide a novel C5a inhibitor used for the treatment of pneumonia, particularly viral pneumonia. An inhibitor of C5a is a binding portion that specifically binds to human C5a, and the binding portion comprises (a) an antibody or an antigen-binding fragment thereof, (b) an oligonucleotide, and (c) an antibody-like fragment. An inhibitor of C5a selected from the group consisting of a protein and (d) a peptidomimetic. It also relates to the use of inhibitors of C5a in the preparation of a pharmaceutical composition for the treatment of pneumonia, especially viral pneumonia. The invention further relates to a method of treating pneumonia, in particular viral pneumonia, comprising the step of administering a therapeutic amount of an inhibitor of C5a to a subject in need thereof. [Selection diagram] None【課題】肺炎、特にウイルス性肺炎の治療に使用される新規C5aの阻害剤の提供。【解決手段】C5aの阻害剤はヒトC5aに特異的に結合する結合部分であり、該結合部分が、（a）抗体又はその抗原結合断片と、（b）オリゴヌクレオチドと、（c）抗体様タンパク質と、（d）ペプチド模倣物と、からなる群から選択される、C5aの阻害剤。また、肺炎、特にウイルス性肺炎の治療のための医薬組成物の調製におけるC5aの阻害剤の使用に関する。本発明は更に、治療量のC5aの阻害剤を、それを必要とする被験体に投与する工程を含む、肺炎、特にウイルス性肺炎を治療する方法に関する。【選択図】なし
